EUVIMEDOpdag EUVIMED
Vergleichsstudie

Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort

Tatsuya Shimomura, Fumihiko Urabe, Katsuki Muramoto, Takafumi Yanagisawa, Wataru Fukuokaya, Keiichiro Mori, Kojiro Tashiro, Kota Katsumi, Hidetsugu Takahashi, Kentaro Yoshihara, Keiichiro Miyajima, Yu Imai and 9 more

The Prostate · 2025

DOI: 10.1002/pros.24898 ↗

At a glance

Vergleichsstudie in The Prostate, 2025. Written by Tatsuya Shimomura and 20 co-authors. Institution: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Major MEDLINE topics: Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents, Hormonal, Androgen Receptor Antagonists, Androgen Antagonists. Cited 5 times so far (Crossref); 14 references. Funded by: The authors received no specific funding for this work..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

The biology of castration‐resistant prostate cancer (CRPC) status between conventional hormonal therapy and upfront androgen signaling inhibitor (ARSI) treatment might be different, and the biological status of prostate cancer after failure of sequential ARSI in conventional hormonal therapy would be the same as CRPC in upfront ARSI. In this study, we evaluate our proposed definition of CRPC in our cohort with propensity score‐matched analysis. Patients and Methods A total of 885 patients diagnosed with metastatic hormone‐sensitive prostate cancer (mHSPC) who received conventional hormonal therapy, upfront androgen receptor signaling inhibitors (ARSI) with or without docetaxel therapy at Jikei University Hospital and its affiliated institutions, were included in this study. We compared survival outcomes between conventional hormonal therapy and upfront ARSI doublet treatment using conventional CRPC definition or our proposed CRPC definition.

Result

CRPC‐free survival (CRPCFS) and cancer‐specific survival (CSS) is significantly better in upfront ARSI (upfront (+)) than upfront (–) group (median CRPCFS is 68 months vs. 18 months, median CSS is not reached (NR) and NR, ( p < 0.0001 and p = 0.0381), respectively) in propensity score‐matched cohort, although overall survival (OS) is not different. Median CSS and OS after conventional CRPC diagnosis is NR (upfront (–)) and 30 months (upfront (+)) ( p = 0.0614), and 37 months (upfront (–)) and 24 months (upfront (+)) ( p = 0.00503). OS is significantly better in upfront (–) than upfront (+) group with conventional CRPC definition. Median CSS and OS after our proposed CRPC diagnosis is 20 months (upfront (–)) and 30 months (upfront (+)) ( p = 0.389), and 20 months (upfront (–)) and 24 months (upfront (+)) ( p = 0.932).

Conclusion

This proposed CRPC definition is thought to reflect the actual biological characteristics of prostate cancer with or without upfront ARSI treatment, and it is thought that the introduction of this definition should be considered when comparing the survival outcome between with or without upfront ARSI treatment.

Subjects

MeSH terms (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAntineoplastic Agents, HormonalAndrogen Receptor AntagonistsAndrogen AntagonistsHumansMalePropensity ScoreAgedMiddle AgedDocetaxelCohort StudiesAged, 80 and overRetrospective StudiesNeoplasm MetastasisAntineoplastic Combined Chemotherapy Protocols

Author keywords

CRPC definitionconventional hormonal therapymHSPCsurvival outcomeupfront ARSI treatment

Substances

DocetaxelAntineoplastic Agents, HormonalAndrogen Receptor AntagonistsAndrogen Antagonists

Authors and institutions

  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Funding

  • The authors received no specific funding for this work.

Cite

APA

Shimomura, T., Urabe, F., Muramoto, K., Yanagisawa, T., Fukuokaya, W., Mori, K., Tashiro, K., Katsumi, K., Takahashi, H., Yoshihara, K., Miyajima, K., Imai, Y., Iwatani, K., Kayano, S., Igarashi, T., Murakami, M., Tsuzuki, S., Yamada, H., Miki, J., …, & JIKEI YAYOI Collaborative Group (2025). Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort. The Prostate. https://doi.org/10.1002/pros.24898

Vancouver

Shimomura T, Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, et al. Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort. The Prostate. 2025. doi:10.1002/pros.24898

BibTeX
@article{Shimomura2025,
  author = {Shimomura, Tatsuya and Urabe, Fumihiko and Muramoto, Katsuki and Yanagisawa, Takafumi and Fukuokaya, Wataru and Mori, Keiichiro and Tashiro, Kojiro and Katsumi, Kota and Takahashi, Hidetsugu and Yoshihara, Kentaro and Miyajima, Keiichiro and Imai, Yu and Iwatani, Kosuke and Kayano, Sotaro and Igarashi, Taro and Murakami, Masaya and Tsuzuki, Shunsuke and Yamada, Hiroki and Miki, Jun and Kimura, Takahiro and JIKEI YAYOI Collaborative Group, JIKEI YAYOI Collaborative Group},
  title = {Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24898}
}
Start for free →